Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button
arrow_left sharing button
arrow_right sharing button

Downstream Process Development

WuXi Biologic’s Downstream Process Development (DSPD) team applies state-of-the-art technology in purification process development, process scale-up, process characterization, and technology transfer to cGMP production. DSDP has extensive experience developing purification schemes for a wide-variety of biologics including: monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, recombinant proteins and antibody fragments.


Product Types Purified by DSPD

Product Types Purified by DSPD 


  • Team 
    • The DSPD team comprises over 140 talented, highly-trained scientists, with greater than 85% holding advanced degrees. In 2020, we have over 50 function leads (FLs) managing more than 100 CMC projects.


  • Lab
    • DSPD has more than 1,000 m2 (11,000 ft2) of lab space dedicated to bench-scale process development and access to an additional 800 m2 (8,600 ft2) in the non-GMP pilot plant. Both areas are equipped with state-of-the-art instruments for processing protein therapeutics.